Biopharma, Inc. Pdl Net Worth

The estimated Net Worth of Biopharma, Inc. Pdl is at least $120 Tysiąc dollars as of 10 June 2019. Biopharma Pdl owns over 6,666,667 units of Evofem Biosciences Inc stock worth over $120,000 and over the last 5 years Biopharma sold EVFM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Biopharma Pdl EVFM stock SEC Form 4 insiders trading

Biopharma has made over 1 trades of the Evofem Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Biopharma bought 6,666,667 units of EVFM stock worth $30,000,002 on 10 June 2019.

The largest trade Biopharma's ever made was buying 6,666,667 units of Evofem Biosciences Inc stock on 10 June 2019 worth over $30,000,002. On average, Biopharma trades about 3,333,334 units every 0 days since 2019. As of 10 June 2019 Biopharma still owns at least 13,333,334 units of Evofem Biosciences Inc stock.

You can see the complete history of Biopharma Pdl stock trades at the bottom of the page.

What's Biopharma Pdl's mailing address?

Biopharma's mailing address filed with the SEC is 932 SOUTHWOOD BOULEVARD, , INCLINE VILLAGE, NV, 89451.

Insiders trading at Evofem Biosciences Inc

Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link oraz Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.

What does Evofem Biosciences Inc do?

evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.

Complete history of Biopharma Pdl stock trades at Evofem Biosciences Inc

Evofem Biosciences Inc executives and stock owners

Evofem Biosciences Inc executives and other stock owners filed with the SEC include:

• Saundra Pelletier,
  President, Chief Executive Officer, Director
• Kelly Culwell,
  Chief Medical Officer
• Saundra Pelletier,
  Pres, CEO & Director
• Thomas Lynch,
  Chairman of the Board
• Russell Barrans,
  Chief Commercial Officer
• Justin File,
  Chief Financial Officer
• Justin J. File,
  Chief Financial Officer
• Russell Barrans,
  Chief Commercial Officer
• Tony O'Brien,
  Independent Director
• William Hall,
  Independent Director
• Colin Rutherford,
  Independent Director
• Gillian Greer,
  Independent Director
• Kim Kamdar,
  Independent Director
• Amy Raskopf,
  IR Contact Officer
• Lisa Rarick,
  Independent Director
• Alexander Fitzpatrick,
  Executive Vice President, General Counsel, Secretary
• Dr. Kelly Culwell M.D.,
  Chief Medical Officer
• Kathy Gallo-Doyle,
  VP of Sales
• Alexander A. Fitzpatrick Esq.,
  Exec. VP, Gen. Counsel & Sec.
• Biopharma, Inc. Pdl,
  10% owner
• Research Corp Acacia,
  10% owner
• Anthony Stephen O'brien,
  Director
• Yan Zhang,
  CFO
• Ltd. Invesco,
  10% owner
• Fund Solutions Ltd Link,
  10% owner